Newswire (Published: Tuesday, August 18, 2020, Received: Tuesday, August 18, 2020, 4:46:28 PM CDT)
Word Count: 535
2020 AUG 18 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Oncology Daily -- Research findings on Oncology - Prostate Cancer are discussed in a new report. According to news reporting from Montreal, Canada, by NewsRx journalists, research stated, “Apalutamide is a next-generation androgen receptor (AR) inhibitor approved for patients with nonmetastatic castration-resistant prostate cancer (CRPC) and metastatic castration-sensitive prostate cancer. We evaluated the pharmacokinetics, safety, and antitumor activity of apalutamide combined with abiraterone acetate plus prednisone (AA-P) in patients with metastatic CRPC (mCRPC).”
Funders for this research include Janssen Research Development, Janssen Global Services, LLC.
The news correspondents obtained a quote from the research from the University of Montreal, “Multicenter, open-label, phase Ib drug-drug interaction study conducted in 57 patients with mCRPC treated with 1,000 mg abiraterone acetate plus 10 mg prednisone daily beginning on cycle 1 day 1 (C1D1) and 240 mg apalutamide daily starting on C1D8 in 28-day cycles. Serial blood samples for pharmacokinetic analysis were collected on C1D7 and C2D8. Systemic exposure to abiraterone, prednisone, and prednisolone decreased 14%, 61%, and 42%, respectively, when apalutamide was coadministered with AA-P. No increase in mineralo-corticoid excess-related adverse events was observed. Patients without prior exposure to AR signaling inhibitors had longer median treatment duration and greater mean decrease in prostate-specific antigen (PSA) from baseline compared with those who had received prior therapy. Confirmed PSA reductions of >= 50% from baseline at any time were observed in 80% (12/15) of AR signaling inhibitor naive patients and 14% (6/42) of AR signaling inhibitor-treated patients. Treatment with apalutamide plus AA-P was well tolerated and showed evidence of antitumor activity in patients with mCRPC, including those with disease progression on AR signaling inhibitors. No clinically significant pharmacokinetic interaction was observed between abiraterone and apalutamide; however, apalutamide decreased exposure to prednisone.”
According to the news reporters, the research concluded: “These data support development of 1,000 mg abiraterone acetate plus 10 mg prednisone daily with 240 mg apalutamide daily in patients with mCRPC.”
For more information on this research see: Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide With Abiraterone Acetate Plus Prednisone In Metastatic Castration-resistant Prostate Cancer: Phase Ib Study. Clinical Cancer Research, 2020;26(14):3517-3524. Clinical Cancer Research can be contacted at: Amer Assoc Cancer Research, 615 Chestnut St, 17TH Floor, Philadelphia, PA 19106-4404, USA. (American Association for Cancer Research - www.aacr.com; Clinical Cancer Research - http://clincancerres.aacrjournals.org/)
Our news journalists report that additional information may be obtained by contacting Fred Saad, University of Montreal, Dept. of Surgery, Montreal, Pq, Canada. Additional authors for this research include Edwin M. Posadas, Kim N. Chi, Ronald de Wit, Maja J. A. de Jonge, Gerhardt Attard, Terence W. Friedlander, Margaret K. Yu, Peter Hellemans, Caly Chien, Charlene Abrams and Juhui J. Jiao.
The direct object identifier (DOI) for that additional information is: https://doi.org/10.1158/1078-0432.CCR-19-3402. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
(Our reports deliver fact-based news of research and discoveries from around the world.)
Janssen Research & Development LLC
Johnson & Johnson
American Association for Cancer Research
Science and Technology
Health and Wellness
Medical Conditions and Diseases
Men's Health Issues
Treatments and Therapies